tbuckley/cabot-search huggingface dataset:
1074P Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy
Authors: H. Arasanz, A.I. Bocanegra Gondan, L. Teijeira, M. Garnica, I. Morilla Ruiz, L. Chocarro, M. Martínez-Aguillo, K. Ausin, E. Blanco, M. Zuazo, G. Fernandez-Hinojal, M. Echaide, L. Fernández-Rubio, S. Pineiro-Hermida, P. Ramos, J. Fernández-Irigoyen, G. Kochan, R. Vera, D. Escors
Journal: Annals of Oncology (2022)
CN71 Evaluating real-world caregiver involvement from a survey of patients (pts) with metastatic urothelial cancer (mUC) receiving systemic anticancer treatment in France, Germany, Italy, Spain, and the UK (Eu5)
Authors: M. La Puente, M. Berry, N. Milloy, R. Montgomery, C. Bleasdale, C. Kluth, M. Kirker, M. Kearney, N. Costa, J. Chang
Journal: Annals of Oncology (2022)
888MO Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors
Authors: R. El Ferkh, J. Hadoux, L. Lamartina, T. Kamoun, L. Cysique-Foinlan, G. Jepiral, M.P. Ducreux, E. Baudin, C. Marzac, J. Baptiste Micol
Journal: Annals of Oncology (2022)
433P Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer
Authors: L. Fernandez-Mañas, F.J. Muñoz i Carrillo, C. Perez-Serrano, H. Oliveres, F.B. De Lacy, A. Otero, R. Bravo, R. Almenara, M. Pages, M.J. Moreno, M. Cuatrecasas, M. Pellise, C. Conill, A. De Lacy, J. Maurel, J-R. Ayuso
Journal: Annals of Oncology (2022)
593P AI-powered analysis of nuclear morphology associated with prognosis in high-grade serous carcinoma
Authors: C.M. Michener, C. Kirkup, B. Rahsepar, J.S. Iyer, J. Abel, K. Leidal, A. Khosla, B. Trotter, M. Lin, M. Resnick, B. Glass, I. Wapinski, F. Najdawi
Journal: Annals of Oncology (2022)
905MO Synergistic combination of clinical, imaging and DNA methylation biomarkers improves the classification of pulmonary nodules
Authors: J. He, B. Wang, J. Tao, Q. Liu, M. Peng, X. Qiu, Y. Yang, Z. Ye, D. Liu, None W. li, Z. Chen, Q. Zeng, J. Fan, W. Liang
Journal: Annals of Oncology (2022)
1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI
Authors: K. Reckamp, M.W. Redman, K. Dragnev, L. Villaruz, B. Faller, T. Al Baghdadi, S. Hines, K. Minichiello, D.R. Gandara, K. Kelly, R.S. Herbst
Journal: Annals of Oncology (2022)
653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial
Authors: H. Mirghani, C. Even, A. Larive, H. Pere, J. Fayette, L. Geoffrois, F. Clatot, B. Calderon, Y. Tao, T.V.F. Nguyen, E. Fabiano, S. Kreps, D. Veyer, J. Puech, C. Badoual, F. Garic, A. Auperin, P. Blanchard
Journal: Annals of Oncology (2022)
54MO Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Authors: A. Lamarca, D. Palmer, H.S. Wasan, P. Ross, Y.T. Ma, A. Arora, S. Falk, R. Gillmore, J. Wadsley, K. Patel, A. Anthoney, A. Maravellas, J.S.C. Waters, C. Hoobs, T. Macdonald, D. Ryder, J. Ramage, L. Davies, J.A. Bridgewater, J.W. Valle
Journal: Annals of Oncology (2022)
832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
Authors: F. Dimitriou, J.C. Hassel, M. Orloff, I. Hughes, E. Kapiteijn, I. Mehmi, K. Montazeri, D.B. Johnson, P. Grover, C.L. Gerard, E. Simeone, C. Gaudy Marqueste, P. Cheng, G.V. Long, R.D. Carvajal, R. Dummer
Journal: Annals of Oncology (2022)
538P Adding plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy increases PFS for patients with platinum-resistant ovarian cancer (updated data)
Authors: Y. Baranau, S. Polyakov, V. Gabai, K. Zharkova, A. Filimonava, V. Siarheyeva, A. Khorau, S. Kazlouskaya, S. Krasny, A. Shneider
Journal: Annals of Oncology (2022)
161P MammaPrint and BluePrint diagnostic tests can be robustly assessed on Whole-Transcriptome NGS platform
Authors: M.C. Liefaard, R. Bhaskaran, Y. Bijl, D. Israeli, S. Jong-Raadsen, E. van Montfort, S. Bao, S. Mee, T. Cavness, A. Gallagher, J. Falk, T. Piel, A. Witteveen, A. van der Voort, S. Vonk, E. Lips, G.S. Sonke, M. Kleijn, A. Glas, L. Mittempergher
Journal: Annals of Oncology (2022)
364P Prevalence, treatment and survival of NTRK gene fusions in microsatellite instable metastatic colorectal cancer patients
Authors: S. Schraa, M.M. Laclé, K. Zwart, E.H. Gort, M. Koopman, W. de Leng, G. Vink, G.M. Bol
Journal: Annals of Oncology (2022)
307P Incidence of neurological symptoms in brain metastases from breast cancer and its impact on prognosis: An analysis of 968 patients with brain metastases
Authors: A. Steindl, K. Schweighart, C. Zach, A. Grisold, B. Gatterbauer, K. Dieckmann, Z. Bago-Horvath, R. Exner, F. Fitzal, G. Pfeiler, C. Singer, G. Widhalm, R. Bartsch, M. Preusser, A.S.S. Berghoff
Journal: Annals of Oncology (2022)
697P Lipid profile as a new diagnostic marker in head and neck cancer
Authors: T.B.D. Castro, G.M. Polachini, L.F.S. Smarra, T. Henrique, R.V.M. López, A.C.D.M. Zeri, I.D.C.G.D. Silva, M. Vandenbosch, R.M. Heeren, E.H. Tajara da Silva
Journal: Annals of Oncology (2022)
1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)
Authors: T. Tokito, A. Hata, S. Hara, M. Tachihara, H. Okada, H. Tanaka, Y. Sato, E. Tabata, H. Watanabe, Y. Takayama, R. Toyozawa, I. Okamoto, K. Wakuda, A. Nakamura, M. Shimokawa, N. Yamamoto, K. Nakagawa
Journal: Annals of Oncology (2022)
945P Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)
Authors: M. García Pardo de Santayana, A. Chang, S. Schmid, M. Dong, D. Christiani, H. Tindle, P. Brennan, C. Chen, Z. Jie, B.M. Ryan, D. Zaridze, M.B. Schabath, R.M. Reis, A. Tardon, S.S. Shete, A. Andrew, H. Brenner, W. Xu, R. Hung, G. Liu
Journal: Annals of Oncology (2022)
729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Authors: I. Melero, M.J. De Miguel, G. Alonso Casal, M-E. Goebeler, E. Ramelyte, E. Calvo, E. Garralda, R. Dummer, M.E. Rodríguez-Ruiz, C.M. Sayehli, M.F. Sanmamed, J.L. Ramón, M.J. Lostes Bardaji, T. Gromke, M.H.H. Schuler, P. Fettes, K. Klar, C. Schuberth-Wagner, J. Wischhusen, E. Leo
Journal: Annals of Oncology (2022)
337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials
Authors: S. Hassanieh, E. Domingo, A. Blake, D. Fisher, K.L. Redmond, S.D. Richman, S.M. Walker, P. Quirke, R.H. Wilson, R. Kennedy, I. Tomlinson, R.S. Kaplan, None L. brown, P. Dunne, M.T. Seymour, D. Morton, R.A. Adams, N. West, T. Maughan
Journal: Annals of Oncology (2022)
277O The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial
Authors: A.J. Brenner, W.T. Phillips, A. Bao, M.H.H. Hedrick, J.E. Michalek, N. LaFrance, T.R. Patel, J. Weinberg, J.R. Floyd
Journal: Annals of Oncology (2022)
146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)
Authors: B. Pellegrino, A. Llop-Guevara, C. Solinas, N. Campanini, C. Tommasi, M. Michiara, D. Boggiani, A. Sikokis, A. Frassoldati, C. Casarini, E. Cretella, G. Zoppoli, M. Lambertini, M.V. Dieci, L. Cortesi, E. Silini, J. Balmaña, K. Willard-Gallo, V. Serra, A. Musolino
Journal: Annals of Oncology (2022)
101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia
Authors: D.S. Tan, Y.M. Kim, M-C. Lim, M. Sho, C-H. Lu, S. Nagao, S. Kubo, B-G. Kim, L-T. Chen, M. Kanai, P-H. Wang, S.Y. Rha, R. Ramar, M.T. Wong, T. Sasaki
Journal: Annals of Oncology (2022)
960P Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression
Authors: M-H. Denault, J. Feng, S. Kuang, A. Shokoohi, B. Leung, M. Liu, E. Berthelet, J. Laskin, S. Sun, T. Zhang, C. Ho, B. Melosky
Journal: Annals of Oncology (2022)
291P Prognosis of glioblastoma according to different TERT promoter mutations
Authors: A. Hernandez Gonzalez, C. Sanz, C.A. Mariño Siancas, M. Domenech Vinolas, G. Parra, A.M. Esteve, C. Carrato, B. Melendez, A. Esteve Codina, A. Martinez-Cardús, F. Alameda, E. Pineda, A. Muñoz, R. Lopez, C. Balana
Journal: Annals of Oncology (2022)
549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study
Authors: T. André, D. Berton-Rigaud, G. Curigliano, R. Sabatier, A.V. Tinker, A. Oaknin, F.G.M. De Braud, S. Ellard, H-T. Arkenau, J.M. Trigo Perez, J. Brown, A. Jewell, J. Pikiel, M.R. Mirza, T. Duan, G. Antony, S. Zildjian, E. Zografos, J. Veneris, S. Banerjee
Journal: Annals of Oncology (2022)
332P Impact of the COVID-19 pandemic in the early-onset colorectal cancer (EOCRC)
Authors: I. Baraibar Argota, A. Garcia Rodriguez, F. Salvà Ballabrera, F.J. Ros Montana, N. Saoudi Gonzalez, R. Comas, G. Castillo, M. Sanchis, J. Hernando Cubero, A. García-Alvarez, J. Capdevila Castillon, M. Martí, S. Landolfi, E. Espin, P.G. Nuciforo, A. Vivancos, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2022)
428P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Preliminary results of TRAP study
Authors: J. Zhang, Q. Dong, Y. WANG, Y. Diao, X. Cui, L. Man, J. Zhang, Y. Zhang, T. Wu, Y. Dong, J. Zhang, Y. Huang, S. Wang
Journal: Annals of Oncology (2022)
360P Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer
Authors: F. Gimeno-Valiente, E. Duréndez, J. Badía, C. Martínez-Ciarpaglini, M. Iglesias, J.L. Linares, M. Huerta, D. Moro, V. Gambardella, J. Martín-Arana, T.C. Fleitas, S. Roselló Keränen, M. Cabeza Segura, B. García-Mico, P. Rentero-Garrido, D. Roda, J. Castillo, A. Cervantes, A. Calon, N. Tarazona Llavero
Journal: Annals of Oncology (2022)
783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)
Authors: A. Spira, R. Mehra, C. Mantia, H. Babiker, M. Borad, A. Cervantes, E. Garralda, A. Mahipal, L. Paz-Ares, C. Hatzis, A. Liu, A. Raue, J. Gan, F. Adrian, L. Manenti, A.B. El-Khoueiry
Journal: Annals of Oncology (2022)
639P Conditional survival in MM and impact of prognostic factors over time
Authors: N. Abdallah, A. Smith, S. Geyer, M. Binder, P. Greipp, P. Kapoor, A. Dispenzieri, M. Gertz, L. Baughn, M. Lacy, S. Hayman, F. Buadi, D. Dingli, Y. Hwa, Y. Lin, T. Kourelis, R. Warsame, R. Kyle, S.V. Rajkumar, S. Kumar
Journal: Annals of Oncology (2022)
924P BLEACH&amp;STAIN, a novel multiplex fluorescence immunohistochemistry framework that facilitates a fast high-throughput analysis of &gt;15 biomarkers in more than 3000 human carcinomas
Authors: E. Bady, K. Möller, N.F. Debatin, T. Mandelkow, C. Hube-Magg, N.C. Blessin
Journal: Annals of Oncology (2022)
230P Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study
Authors: E. Agostinetto, C. De Angelis, M. Brandão, P. Flamen, M. Piccart, E. de Azambuja, G. Gebhart
Journal: Annals of Oncology (2022)
825P CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
Authors: G. Rabinowits, J. Homsi, S.J. Park, N. Khushanlani, T. Panella, D.M. Ellison, R.W. Gentry, S.S. Venna, J. Strasswimmer, R.M. Zuniga, S. Chandra, E.S. Ruiz, M.R. Migden, S. Ibrahim, N. Mehta, X. He, H. Zhang, K.A. Gillis, J-F. Pouliot
Journal: Annals of Oncology (2022)
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Authors: O. Hamid, A. Weise, T.M. Kim, M.A. Mckean, N.J. Lakhani, J. Kaczmar, K.P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, G. Gullo
Journal: Annals of Oncology (2022)
678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Authors: B. Cirauqui Cirauqui, J. Martinez Trufero, M. Plana Serrahima, A. García Castaño, J. Rubió-Casadevall, A. Carral Maseda, L. Iglesias Docampo, P. Pérez Segura, I. Ceballos Lenza, V. Gutierrez Calderon, J. Fuster Salva, C. Pena Álvarez, V. Arrazubi Arrula, E. del Barco Morillo, M. Chaves Conde, J. Martínez Galán, M. Durán Sánchez, V. Quiroga, E. Ortega, R. Mesia Nin
Journal: Annals of Oncology (2022)
437TiP Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator’s choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
Authors: D. Paez, F. Meriggi, C. Cremolini, G. Folprecht, I. Korantzis, E. Chan, Q. Tran, M.G. Fakih
Journal: Annals of Oncology (2022)
961P Prospective real-world data of immuno(chemo)therapy (IO) prior to resection, definitive chemo-radiotherapy (CRT), or palliative therapy in patients with non-small cell lung cancer (NSCLC) without a primary curative option
Authors: K. Lehrach, S. Fallscheer, B. Schwenk, S. Kramberg, S. Eschmann, J. Sträter, F. Heinzelmann, R. Sätzler, M. Faehling
Journal: Annals of Oncology (2022)
937P Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study
Authors: J.B. Auliac, Y. Simmoneau, P.A. Thomas, F. Guisier, O. Bylicki, H. Curcio, A. Swalduz, M. Wislez, M. Geier, None J. Le Treut, C. Decroisette, L. Falchero, J. Tricard, D. Moreau, E. Huchot, G. De Chabot, K. Leroy, A. Lupo Mansuet, C. Chouaid, L. Greillier
Journal: Annals of Oncology (2022)
470P Preclinical assessment of the pharmacokinetics, disposition, and duration of action of the dual alphav-integrin and neuropilin-1 targeting peptide CEND-1
Authors: H.A. Järveläinen, C. Schmithals, M. von Harten, T.J. Vogl, C. Henson, G. Bullen-Clerkson, S. Harris, A. Piiper
Journal: Annals of Oncology (2022)
987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study
Authors: M. Wang, J.C-H. Yang, P. Mitchell, J. Fang, W. Nian, C.H. Chiu, J. Zhou, Y. Zhao, W-C. Su, D.R. Camidge, T-Y. Yang, V. Zhu, M. Millward, Y. Fan, Y. Cheng, L. Jiang, L. Zheng, P.A. Jänne
Journal: Annals of Oncology (2022)
64P Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
Authors: M. Ueno, C. Morizane, M. Ikeda, M. Ozaka, F. Nagashima, T. Kataoka, J. Mizusawa, A. Ohba, S. Kobayashi, H. Imaoka, A. Kasuga, N. Okano, Y. Nagasaka, None K. Kurishita, S. Tomatsuri, M. Sasaki, T. Shibata, K. Nakamura, J. Furuse, T. Okusaka
Journal: Annals of Oncology (2022)
688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC)
Authors: M. Moutafi, P. Economopoulou, I. Kotsantis, M. Anastasiou, P. Foukas, G. Fountzilas, D. Rimm, A. Psyrri
Journal: Annals of Oncology (2022)
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy
Authors: T. Hakozaki, A. Nolin-Lapalme, M. Kogawa, Y. Okuma, S. Nakamura, T. Tamura, Y. Hosomi, H. Takeyama, C. Richard, M. Hosokawa, B. Routy
Journal: Annals of Oncology (2022)
175P Patients’ experiences of a suppoRted self-manAGeMent pAThway in breast cancer (PRAGMATIC): Quality of life results
Authors: M. Teoh, None I. Solis- Trapala, None L. matthews, S. May, M. Kothari, D. Bloomfield, C. Zammit, D. Betal, R. Santos, E. Stewart, J. Finlay, K. Nicholson, D. Elwell-sutton, H. Gage, S. Bell, F. McKinna, V.A. Jenkins
Journal: Annals of Oncology (2022)
250P Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database
Authors: C.C. Courtinard, S. Gourgou, W. Jacot, None M. Carton, T. Filleron, D. Couch, B. Asselain, M-C. Le Deley, L. Vacher, A. Antoine, D. Parent, None R. Schiappa, M. Breton, S. Michiels, E.G.C. Brain, O. Guérin, A. Loeb, G. Perrocheau, G. Simon, C. Bellera
Journal: Annals of Oncology (2022)
CN67 Scattered ward care: The importance of appropriate nursing skill mix in managing oncology inpatients
Authors: M. Clarke, M. O'Connor, C. Cluxton, E. Farrell, O.M. Fitzpatrick, L. Keogh, W.M. Grogan, D.J. McMahon, A.G. Murphy, L. Judge, M. Conroy, J. Naidoo, C. Matassa, R.A. Mclaughlin, P.G. Morris, B.T. Hennessy, K. Egan, C. O'Shea, D. O'Doherty, O.S. Breathnach
Journal: Annals of Oncology (2022)
1072P Prognostic role of immune checkpoints mRNA expression in peripheral blood of non-small cell lung cancer patients treated with immune checkpoint inhibitors
Authors: C. Papadaki, A. Monastirioti, K. Rounis, D. Kalapanida, G. Kousoulis, K. Michaelidou, E. Vorrias, M.A. Papadaki, D. Mavroudis, S. Agelaki
Journal: Annals of Oncology (2022)
1001P Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
Authors: Z. Piotrowska, M. Lin, Y. Yin, E. Curran, V. Crossland, Y. Wu, S-H.I. Ou
Journal: Annals of Oncology (2022)
802P Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study
Authors: S. Martín Algarra, A. Piñero Madrona, M-Á. Berciano-Guerrero, E. Muñoz Couselo, A. Soria, J.L. Manzano, L. Gutiérrez Sanz, G. Crespo, T. Puértolas, A. García Castaño, C. Aguado de la Rosa, E. Espinosa, M. Majem, R. López Castro, P. Ayala de Miguel, J. Medina Martínez, L.A. Fernández-Morales, L. Bellido, P. Cerezuela-Fuentes, I. Márquez-Rodas
Journal: Annals of Oncology (2022)
511P HIV impact in localized anal carcinoma: A matched cohort study
Authors: A. Acioli de Almeida, E. Rocha, R. Colombo Bonadio, D. Galhera, M.I. Braghiroli, L.B. Alban, C.R. Victor, A.F.L. Dornellas, M. Polo Mingueti e Silva, C.S. Araujo de Carvalho, A. Bueno, C. Nahas, K. Ibrahim, A. Chen, P.M. Hoff, C. Motta Venchiarutti Moniz
Journal: Annals of Oncology (2022)
435P Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study
Authors: R.S.P. Riechelmann, A. Kruschewsky Coutinho Araujo, G. dos Santos Fernandes, R. Weschenfelder, D.R.D. Rocha Filho, L.A. Schlittler, J.F.D.M. Rego, G. Prolla, R.G. de Jesus, G.C.D.L. Gössling, R. D'Alpino Peixoto
Journal: Annals of Oncology (2022)
1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC
Authors: A. Marinello, D. Vasseur, N. Conci, V. Fallet, C. Audigier-Valette, S. Cousin, F. Tabbò, F. Guisier, A. Russo, A. Calles Blanco, G. Metro, G. Massa, F. Citarella, A.K. Eisert, P. Iranzo Gomez, M. Tagliamento, L. Mezquita, C. Lindsay, S. Ponce, M. Aldea
Journal: Annals of Oncology (2022)
218P Patient-reported quality of life in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4
Authors: X. Hu, E. Broughton, W. Li, T. Sun, K. Shen, C. Huang, V. Sriuranpong, K.C.R. Ngan, Y.H. Chia, H. Bhattacharyya, H. Zhao, J. Shen, B. Xu
Journal: Annals of Oncology (2022)
879P Whole-genome landscape of head and neck melanomas in East Asia (China)
Authors: X. Wang, W. Wu, X. Wu, L. Si, Z. Chi, X. Sheng, L. Li, W. Han, H. Li, B. Lian, L. Zhou, L. Mao, X. Bai, T. Bixia, X. Wei, C-L. Cui, Y. Kong, J. Guo
Journal: Annals of Oncology (2022)
179P Does undertreatment of elderly patients with early breast cancer impact outcome?
Authors: J. Monteiro Vasconcellos, R. Colombo Bonadio, S. Vidaurre Mendes, B. Zanin Orsi, L. Vecchi Leis, A.P. Messias, O.A. Moreira, M. Baptista Pereira, P.J. Galvão Freir, A. Rodrigues De Araujo Neto, E. Andrade Rocha, V. Petry, L. Testa
Journal: Annals of Oncology (2022)
940P Programmed death-ligand 1 (PDL1) expression and real-world outcomes in resected, early-stage non-small cell lung cancer (NSCLC)
Authors: P.K. Cheema, I. Syed, F. Gwadry-Sridhar, M. Rakibuz-Zaman, R. Sachdeva, A. Pencz, L.J. Zhan, K. Hueniken, D. Patel, K. Balaratnam, K. Khan, B. Grant, S. Noy, K. Singh, B.S. Sheffield, B. Locke, D. Moldaver, M.K. Shanahan, G. Liu, M.S. Kuruvilla
Journal: Annals of Oncology (2022)
404P A quantitative synthesis of disparities in the inclusion of younger adults and racial/ethnic minorities in colorectal cancer clinical trials
Authors: I.B. Riaz, S.A.A. Naqvi, M. Islam, W. Ikram, U. Raza, A. Ayaz, A. Riaz, H. Amna, H. Maqsood, Z. Jin, M.B. Sonbol
Journal: Annals of Oncology (2022)
452O A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
Authors: P. Schoeffski, N. Yamamoto, T. Bauer, M. Patel, M.M. Gounder, J. Geng, R. Sailer, G. Jayadeva, P. Lorusso
Journal: Annals of Oncology (2022)
486P AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein, elicits potent anti-tumor efficacy in pre-clinical studies
Authors: J. Min, Z. Huang, X. Pang, T. Zhong, C. Jin, N. Chen, D. Xia, P. Zhang, Z.M. Wang, Y. Xia, B. Li
Journal: Annals of Oncology (2022)
369P Irinotecan is superior to oxaliplatin in KRAS-G12C-mutated (K-G12C-m) colorectal cancer (CRC) and should be preferred in combination strategies with K-G12C inhibitors. A multicenter propensity score-matched (PSM) retrospective analysis
Authors: C. Morelli, J. Lucchetti, M.A. Calegari, M. Rofei, S. Guerriero, S. Riondino, V. Flaminio, G. Parisi, F. Lo Prinzi, G. Trovato, B. Vincenzi, L. Salvatore, M. Roselli, V. Formica
Journal: Annals of Oncology (2022)
834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)
Authors: M.F. Silva Almeida Ribeiro, T. Pimentel Muniz, P. Jablonska, I. Hirsch, M. Vilbert, E.C. Koch, L. Mantle, S. Saibil, A. Spreafico, D. Hogg, D. Shultz, M.O. Butler
Journal: Annals of Oncology (2022)
655MO Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016
Authors: J. Ringash, L. DeMora, M.L. Gillison, D.J. Adelstein, P. Harari, E.M. Sturgis, E.M. Basch, S.A. Koyfman, G.A. Krempl, D.M. Blakaj, J.E. Bates, T. Galloway, C.U. Jones, B.M. Beadle, P. Torres-Saavedra, Q-T. Le, B. Movsas
Journal: Annals of Oncology (2022)
991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
Authors: A. Kron, M. Scheffler, M. Ihle, S. Michels, J. Süptitz, D. Prang, F. Jakobs, L. Nogova, R.N. Fischer, A.K. Eisert, R. Riedel, F. Kron, A. Hillmer, S. Loges, S. Merkelbach-Bruse, R. Büttner, J. Wolf
Journal: Annals of Oncology (2022)
519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
Authors: A. Oaknin, B.J. Monk, L. Polastro, A. Cristina de Melo, H.S. Kim, Y.M. Kim, A.S. Lisyanskaya, V. Samouëlian, D. Lorusso, F.B. Damian, C-L. Chang, S. Takahashi, D. Ramone, B. Maćkowiak-Matejczyk, J. Li, S. Jamil, M.D. Mathias, M.G. Fury, K.S. Tewari
Journal: Annals of Oncology (2022)